264 related articles for article (PubMed ID: 31400279)
1. NFAT2-HDAC1 signaling contributes to the malignant phenotype of glioblastoma.
Song Y; Jiang Y; Tao D; Wang Z; Wang R; Wang M; Han S
Neuro Oncol; 2020 Jan; 22(1):46-57. PubMed ID: 31400279
[TBL] [Abstract][Full Text] [Related]
2. Cell surface GRP78 regulates BACE2 via lysosome-dependent manner to maintain mesenchymal phenotype of glioma stem cells.
Chen Z; Wang H; Zhang Z; Xu J; Qi Y; Xue H; Gao Z; Zhao R; Wang S; Zhang S; Qiu W; Guo X; Li G
J Exp Clin Cancer Res; 2021 Jan; 40(1):20. PubMed ID: 33413577
[TBL] [Abstract][Full Text] [Related]
3. lncRNA LINC01057 promotes mesenchymal differentiation by activating NF-κB signaling in glioblastoma.
Tang G; Luo L; Zhang J; Zhai D; Huang D; Yin J; Zhou Q; Zhang Q; Zheng G
Cancer Lett; 2021 Feb; 498():152-164. PubMed ID: 33130316
[TBL] [Abstract][Full Text] [Related]
4. FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells.
Cheng P; Wang J; Waghmare I; Sartini S; Coviello V; Zhang Z; Kim SH; Mohyeldin A; Pavlyukov MS; Minata M; Valentim CL; Chhipa RR; Bhat KP; Dasgupta B; La Motta C; Kango-Singh M; Nakano I
Cancer Res; 2016 Dec; 76(24):7219-7230. PubMed ID: 27569208
[TBL] [Abstract][Full Text] [Related]
5. NFAT1-Mediated Regulation of NDEL1 Promotes Growth and Invasion of Glioma Stem-like Cells.
Jiang Y; Song Y; Wang R; Hu T; Zhang D; Wang Z; Tie X; Wang M; Han S
Cancer Res; 2019 May; 79(10):2593-2603. PubMed ID: 30940662
[TBL] [Abstract][Full Text] [Related]
6. miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-κB pathways in glioblastoma.
Yang F; Liu X; Liu Y; Liu Y; Zhang C; Wang Z; Jiang T; Wang Y
Cancer Lett; 2017 Jun; 396():1-9. PubMed ID: 28286260
[TBL] [Abstract][Full Text] [Related]
7. The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells.
Kim SH; Kim EJ; Hitomi M; Oh SY; Jin X; Jeon HM; Beck S; Jin X; Kim JK; Park CG; Chang SY; Yin J; Kim T; Jeon YJ; Song J; Lim YC; Lathia JD; Nakano I; Kim H
Cell Death Differ; 2015 Sep; 22(9):1517-25. PubMed ID: 25721045
[TBL] [Abstract][Full Text] [Related]
8. Stem cell signature in glioblastoma: therapeutic development for a moving target.
Nakano I
J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
[TBL] [Abstract][Full Text] [Related]
9. ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem cells.
Gao Z; Xu J; Fan Y; Zhang Z; Wang H; Qian M; Zhang P; Deng L; Shen J; Xue H; Zhao R; Zhou T; Guo X; Li G
J Exp Clin Cancer Res; 2022 Nov; 41(1):323. PubMed ID: 36380368
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K/AKT and MEK/ERK signaling pathways.
Li S; Chen X; Mao L; Zahid KR; Wen J; Zhang L; Zhang M; Duan J; Duan J; Yin X; Wang Y; Zhao L; Tang X; Wang X; Xu G
Brain Res; 2018 Aug; 1692():154-162. PubMed ID: 29782850
[TBL] [Abstract][Full Text] [Related]
11. HDAC1 mediates epithelial-mesenchymal transition and promotes cancer cell invasion in glioblastoma.
Cheng Z; Li S; Yuan J; Li Y; Cheng S; Huang S; Dong J
Pathol Res Pract; 2023 Jun; 246():154481. PubMed ID: 37121053
[TBL] [Abstract][Full Text] [Related]
12. Tenascin C promotes cancer cell plasticity in mesenchymal glioblastoma.
Angel I; Pilo Kerman O; Rousso-Noori L; Friedmann-Morvinski D
Oncogene; 2020 Nov; 39(46):6990-7004. PubMed ID: 33077835
[TBL] [Abstract][Full Text] [Related]
13. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
14. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma.
Bhat KP; Salazar KL; Balasubramaniyan V; Wani K; Heathcock L; Hollingsworth F; James JD; Gumin J; Diefes KL; Kim SH; Turski A; Azodi Y; Yang Y; Doucette T; Colman H; Sulman EP; Lang FF; Rao G; Copray S; Vaillant BD; Aldape KD
Genes Dev; 2011 Dec; 25(24):2594-609. PubMed ID: 22190458
[TBL] [Abstract][Full Text] [Related]
15. LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients.
Xie Y; Sundström A; Maturi NP; Tan EJ; Marinescu VD; Jarvius M; Tirfing M; Jin C; Chen L; Essand M; Swartling FJ; Nelander S; Jiang Y; Uhrbom L
J Pathol; 2019 Feb; 247(2):228-240. PubMed ID: 30357839
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6.
Xi Z; Wang P; Xue Y; Shang C; Liu X; Ma J; Li Z; Li Z; Bao M; Liu Y
Oncotarget; 2017 Apr; 8(15):24949-24963. PubMed ID: 28212562
[TBL] [Abstract][Full Text] [Related]
17. Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells.
Shi Y; Zhou W; Cheng L; Chen C; Huang Z; Fang X; Wu Q; He Z; Xu S; Lathia JD; Ping Y; Rich JN; Bian XW; Bao S
Cell Death Differ; 2017 Jan; 24(1):167-180. PubMed ID: 27740621
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus infection promotes the formation of glioma stem cells from glioblastoma cells through the TLR9/NEAT1/STAT3 pathway.
Zang J; Zheng MH; Cao XL; Zhang YZ; Zhang YF; Gao XY; Cao Y; Shi M; Han H; Liang L
Cell Commun Signal; 2020 Aug; 18(1):135. PubMed ID: 32843056
[TBL] [Abstract][Full Text] [Related]
19. RUNX1 contributes to the mesenchymal subtype of glioblastoma in a TGFβ pathway-dependent manner.
Zhao K; Cui X; Wang Q; Fang C; Tan Y; Wang Y; Yi K; Yang C; You H; Shang R; Wang J; Kang C
Cell Death Dis; 2019 Nov; 10(12):877. PubMed ID: 31754093
[TBL] [Abstract][Full Text] [Related]
20. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
